Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild-to-moderate pain and symptoms of inflammatory conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute migraine attacks. It is also indicated for primary dysmenorrhea and other painful conditions. Diclofenac works primarily by inhibiting cyclooxygenase enzymes (COX), especially COX-2, thereby reducing the synthesis of prostaglandins responsible for pain, inflammation, and fever. It is available in multiple formulations including oral tablets (immediate-release, delayed-release/enteric-coated, extended-release), capsules (including liquid-filled), powder for solution, topical gels/patches/solutions, rectal suppositories, ophthalmic solutions (eye drops), intramuscular injection, and intravenous injection[1][3][5][9]. Diclofenac does not cure underlying diseases but provides symptomatic relief as long as it is taken.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diclofenac.